A New Short Infusion Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Venous Thromboembolic Disease
- 31 March 1990
- Vol. 97 (4), 168S-171S
- https://doi.org/10.1378/chest.97.4_supplement.168s
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patencyJournal of the American College of Cardiology, 1989
- BOLUS STREPTOKINASE AFTER MYOCARDIAL INFARCTIONThe Lancet, 1987
- Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator.Journal of Clinical Investigation, 1987
- Optimal Dosage Regimens of Tissue-Type Plasminogen ActivatorSeminars in Thrombosis and Hemostasis, 1987
- Tissue-Type Plasminogen ActivatorDrugs, 1986
- A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits.Circulation, 1985
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985
- Intravenous urokinase in acute myocardial infarctionThe American Journal of Cardiology, 1985
- Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial.Circulation, 1984
- THE MAINTENANCE OF A SUSTAINED THROMBOLYTIC STATE IN MAN. I. INDUCTION AND EFFECTS*Journal of Clinical Investigation, 1959